All posts by The Trauma Pro

Abstracts

EAST 2019 #7: Falls Screening In The Elderly

Leave a comment

Falls in our elderly population are one of the largest issues facing trauma centers in the US, if not world-wide. The sheer numbers, along with the significant morbidity and mortality experienced by this group is mind boggling. ACS verified trauma centers are encouraged to have geriatric specific practice guidelines to assist in optimal care of these patients, and falls prevention programs are common among them.

The Centers for Disease Control is promoting a program called the Stopping Elderly Accidents, Deaths, and Injuries (STEADI) initiative. They provide a suite of tools and resources, and screening begins with a 12 point questionnaire (see links). This tool obviously takes a bit of time to administer, and time is precious. The research group at
Baystate Medical Center in Massachusetts postulated that giving the full screen may be a bit cumbersome.

They explored a possible simplification to the 12-point STEADI screen, reducing it to only 3 of the questions. They sought to determine whether this easier and more convenient screen might be as accurate as the full STEADI screen. They evaluated a group of 60 elderly patients use the abbreviated tool, and those who scored high were referred to a physical therapy for further assessment and intervention. The primary outcome was performance improvement on the Timed Up and Go test (TUG), a measure of the patient’s ability to get up from a chair, walk a fixed distance and back, then sit down again. Normal performance is < 12 seconds.

Here are the factoids:

  • The median age of the 60 study patients who were considered high risk was 77
  • Median TUG before interventions was 16 seconds
  • After physical therapy intervention, the time decreased significantly to 12.3 seconds

The authors concluded that the abbreviated screen could be used to effectively identify elderly patients at risk for falls.

Here are some questions for the authors and presenter to consider in advance to help them prepare for audience questions:

  • Show the audience the full STEADI questionnaire, and highlight the three questions used in your study. This was not specified in the abstract. Did the patients have to score positive on all three questions to qualify for intervention?
  • How much time difference is there in answering the full 12-question survey vs the abbreviated 3 question one? The full survey looks pretty simple to me.
  • Did you also administer the full screen to see the correlation with your subset of three questions? This could provide interesting information that could validate the brief screen. How many more receiving the full screen would have qualified for the intervention?
  • What exactly were the interventions that the therapists provided in PT? Were they the same for each patient? How do you think they improved the TUG score?
  • Did all 60 patients complete the program? Or were more enrolled and only 60 qualified for intervention?
  • Is the TUG score difference clinically significant? You showed statistical significance, but are these patients really less likely to fall? Did you collect any data of falls after completion of the intervention?

This is a timely and pertinent study. I look forward to hearing the nitty gritty at the conference.

Links:

  • The STEADI algorithm
  • The 12 point STEADI screen

Reference: Fall prevention initiative: A fall screening pilot study in the ambulatory setting. EAST 2019 Paper #21.

Abstracts

EAST 2019 #6: Trauma Prevention and Your Trauma Registry

Leave a comment

Trauma centers verified by the American College of Surgeons (ACS) (and most states who perform their own designation visits) are required to engage in trauma prevention activities. Furthermore, ACS centers are required to provide prevention programs based on identified local needs. Frequently, trauma professionals see a pattern of injury in the patients they treat. This generally stimulates a search through their trauma registry. Reviewing registry data is the most direct way of identifying and confirming injury patters specific to the local population.

The next abstract for review describes the process and outcomes of such a project from a Level II center in Fort Walton Beach, Florida. They noted a pattern of diving injury and high cervical fractures. This was confirmed using 2016 registry data. Admitted patients were intensive resource users, with 71% requiring ICU admission and operative fixation, and nearly half requiring rehab admission upon discharge.

Based on this, they developed a “Think Before You Dive” program with posters, signs, swag (a custom koozie), a trifold brochure, and magnets with diving and water safety tips. Posters and flyers were provided to local business, and magnets were placed in hotel rooms in the area. One time-share company even placed a hard stop in their registration process so that visitors had to acknowledge the safety message.

What’s a koozie, you ask? I didn’t know the technical term for this, but here’s a picture:

Here are the factoids:

  • There was a reduction of 100% in cervical spine injuries, and 24% of all water-related incidents in the targeted area
  • All remaining diving/high-cord injuries came from outside the target area
  • It was estimated that costs were reduced by $1.2 million

As you can see, this is not the typical hard research paper usually provided at most scientific meetings. However, it is very important that this kind of information is presented, as it has the potential for impact on the other clinical research.

Here are some questions for the authors and presenter to consider in advance to help them prepare for audience questions:

  • How did you recognize the problem initially? Was it a pattern picked up by humans? Which ones (nurses, trauma physicians, therapists/rehab, others)?
  • Why did you think that your prevention approach would be effective?
  • Provide some details on how you convinced businesses to carry your message. Was there any resistance, and what were their arguments? How did you overcome it?
  • Show us the numbers. Although it may be difficult to show statistical differences in patient numbers, cost savings is important as well. Show the patient numbers pre- and post-intervention for the cluster area and outside of it.
  • Define how you arrived at your cost savings numbers. How do the previously published economic numbers relate to costs at your own center and those reported in this study?

I believe that this is important information, and will help many other centers properly design their own trauma prevention programs!

Reference: Using the trauma registry to guide your injury prevention programs. EAST 2019 Paper #18.

Abstracts

EAST 2019 #5: Safety Of Whole Blood

Leave a comment

What goes around comes around. Fifty years ago, blood banks began fractionating whole blood into separate products so that specific component therapy could be administered. Over a relatively brief period of time, the switch to components became nearly complete, and whole blood was not available for civilian use. For decades, trauma professionals have had to treat our trauma patients losing whole blood, but having only components available to replace it. Unfortunately, taking blood apart and putting it back together just isn’t the same, as you can see below:

In recent years, there has been a significant movement to reintroduce whole blood. Many trauma centers are experimenting with it, and it seems we are having to relearn how to use it again. At last year’s EAST meeting, the US Army Institute of Surgical Research presented a paper that demonstrated improved survival in select severely injured patients. This year, an abstract from the University of Texas in Houston is being presented that explores the safety of giving whole blood.

This was a single-hospital study where cold-stored low titer type O whole blood (WB) was stocked in the center’s helicopters and emergency department. Components were also available. The center reviewed their 7 month experience with trauma patients who received either type of product. Their outcome variables were safety profile and transfusion reaction rates.

  • 161 patients received component therapy and 95 received WB during the study period
  • ISS was statistically similar, but the abbreviated injury score for chest was higher in the whole blood group (see first two bullet points below)
  • Whole blood patients were more markedly impaired in the prehospital setting (higher pulse and lactate, lower blood pressure)
  • Whole blood patients received fewer units of products after leaving the ED, which is an 80% reduction when matched for the usual variables (0 vs 3)
  • Mortality was the same in the two groups (26% WB vs 22% component)
  • There was only one transfusion reaction, and it occurred in the component group

The authors concluded that whole blood appeared to be a safe alternative to 1:1 component therapy, and was associated with a reduced need for post-ED transfusion.

  • How were patients selected to receive components vs whole blood? Or were they? This could potentially influence many of the variables you analyzed (vital signs, lab values). Be sure to explain how selection bias may have influenced your results.
  • Some of your variables are statistically similar (i.e. ISS) but clinically different, or vice versa (24 hour bilirubin, chest AIS). Be prepared to explain why these results are or are not meaningful.
  • What do the terms safety profile and impact mean in your objectives section. You mention transfusion reaction rate separately, so what other safety and impact factors were you measuring?
  • Once again, statistical power is a question. Did you do a power analysis? I worry that a difference of 1 transfusion reaction in 250 patients was used to call whole blood safe.
  • How do you know the decrease in post-ED transfusions was due to use of whole blood? Please make sure to summarize the resuscitation given to the two groups while they were in the ED. Did the component group receive fewer units in the ED, thus requiring more afterwards? And vice versa for the whole blood group. Did they get more enroute to the hospital and in the ED?

This was a very interesting abstract. I’m looking forward to hearing many more details when you present.

Reference: Safety profile and impact of low-titer group O blood for emergency use in trauma. EAST 2019 Paper #16.

Abstracts

EAST 2019 #4: Predicting Retained Hemothorax

Leave a comment

Traumatic hemothorax is an interesting problem. Sometimes it clots, sometimes it doesn’t. Sometimes it sticks to the lung and causes a restrictive problem, sometimes it doesn’t. And even if it doesn’t fuse to the lung, having a moderate volume of retained blood can create significant functional problems.

What if we could predict which hemothoraces would progress to retained hemothorax so we could intervene sooner and avoid complications and potential wasted time in the hospital? An EAST multi-institutional trial explored a possible technique for doing just that, postulating that an initial large volume hemothorax (HTX) would correlate with development of retained HTX. This study used data collected prospectively from 17 US trauma centers, and involved the use of Mergo’s formula to calculate the size of the HTX. This technique essentially estimates the volume of a cylinder that fits inside the largest diameter of the HTX seen on CT scan, extending the entire length of the thorax. Although this technique will underestimate the volume at the largest part of the HTX, it overestimates it above and below this point, so it probably all evens out. Roughly.

Here are the factoids:

  • 985 patients were enrolled and 1033 HTX were measured
  • Patients who developed retained HTX (defined as blood in the chest requiring intervention or subsequent identification of HTX by CT) were more likely to have penetrating trauma, pulmonary contusion, and had their HTX seen on initial chest x-ray (CXR)
  • Chest abbreviated injury score (AIS) was higher in patients with retained HTX, and their calculated HTX volume was larger
  • Chest tube size did not correlate with development of retained HTX
  • The authors concluded that patients who developed retained HTX had a lower initial hematocrit, higher chest AIS, and large volume seen on CT

Here are some questions for the authors and presenter to consider in advance to help them prepare for audience questions:

  • When and over what period of time was this data collected? It was not stated in the abstract. Very old or long-running data sets run the risk of technology (CT scan resolution) or practice (pigtail vs chest tube) changes.
  • Couldn’t the hematocrit and chest AIS factors be red herrings? Did this study look at all the other injuries that could have decreased the hematocrit or just focus on the chest injury? And the chest AIS automatically increases from 3 to 4 as the volume of the HTX increases. Could this skew your analysis?
  • One of the definitions of retained HTX (need for intervention) depends on clinical judgement and practice habits, which probably differ at the various trauma centers enrolled.
  • Only odds ratios were listed in the abstract. Even though the HCT and AIS numbers are statistically significantly different, I can’t tell if they are clinically significant. Be sure to share your means and standard deviation/error during your presentation.
  • Did you lump pigtail catheters in with regular chest tubes? And did you look at the distribution of chest tube sizes? If all were large it would be hard to come to a good conclusion about size.
  • What about trauma centers who do not use CT on every trauma patient? Do we really need to CT someone who falls down, breaks a few ribs, and has a visible HTX on CXR?
  • Big picture: so what do we do now based on your findings? How do we plan re-imaging and potential surgical intervention in these patients?

This is very interesting work, and I look forward to the presentation!

Reference: Predictors of post-traumatic retained hemothorax: results of an EAST multi-institutional trial. EAST 2019 Paper #14.

Abstracts

EAST 2019 #3: Chest Tube vs Pigtail

Leave a comment

I love stuff about chest tubes. There are so many opinions and so little data to back them up. And now here’s another EAST 2019 Annual Assembly paper from the University of Arizona at Tucson on chest tubes! The traditional dogma, and something that I’ve promoted for some time, is that the only size chest tube that should be used for hemothorax is big (36 Fr) or bigger (40 Fr). There have been a few abstracts and published papers over the past 7 years that are trying to change this assumption. Will they be successful?

The first work on this was a paper published in 2012 by this same group in Tucson. It was a prospective study that included 36 patients with pigtails and 191 with 32 Fr – 40 Fr chest tubes over 30 months. Average initial drain output was the same, and there were no differences in tube in time, complications, or failure rate.

A related abstract was then presented by this group at the 2013 EAST Annual Assembly, but it doesn’t look like this one got published. It was a small, prospective study that enrolled 40 of 72 eligible patients over 20 months and compared pigtail catheters vs 28 Fr chest tubes. They found that chest wall and tube site pain was less with a pigtail, and that failure and complication rates, tube in time, and hospital stay were the same.

And then in 2017 more related work was presented at EAST from the group, and was later published in the World Journal of Surgery. This study was the culmination of 7 years of experience, and included nearly 500 subjects. Once again, initial drainage output was the same, as were complications and failure rate. The authors concluded that a multi-center trial was need to provide additional support.

And that brings us up to EAST 2019. Now the authors are presenting a single-center study comparing 14 Fr pigtail vs 28-36 Fr chest tubes for hemothorax and pneumthorax. What’s different about this one? For the first time, the subjects were randomized between pigtail and chest tube in an effort to eliminate selection bias.

Here are the factoids:

  • A total of 43 patients were enrolled, but the number excluded was not given
  • Although baseline characteristics of the two groups were identical, several differences approached clinical significance: percent blunt trauma, flail chest, insertion day, and initial chest tube output
  • The authors concluded that there were no differences in initial chest tube output, failure rate, tube days, and lengths of stay. However, perceived pain was less.
  • They again noted that a multi-center trial should be performed to confirm these results

Here are some questions for the authors and presenter to consider in advance to help them prepare for audience questions:

  • What’s new and different with this study? The University of Arizona – Tucson has been studying pigtails since 2009. Tell us about the progression of this work and how the current study fits in.
  • How many patients were excluded? This is very important, especially if this number is high. What were the exclusion criteria exactly?
  • What did your power analysis show? The overall enrollment numbers are low, which may throw your statistics into doubt. This is especially true since your primary outcome showed that pigtail and chest tube outputs were the same but with a p=0.06! More patients may have helped show the desired difference.
  • Were the pigtail and chest tube groups really “similar?” There were more penetrating injuries in the chest tube group. Could this have an impact on clotted vs non-clotted blood in the chest and the ability of a pigtail to drain it? And the median pigtail insertion date was 1.5 days later than for chest tubes, which is clinically significant. Could this allow time for defibrination of the hemothorax, resulting in better drainage?
  • And what’s next? Will I see you again at EAST 2020 or 2021 with a larger prospective study? Or a multi-center one?

I’m looking forward to hearing this one in person!

References:

  • A single center prospective randomized study comparing the effectiveness of 14 French percutaneous catheters (pigtail) versus 28-36 French chest tube in the management of traumatic hemothorax/hemopneumothorax. EAST 2019 Paper #13.
  • EAST abstract presentation 2013.
  • EAST abstract presentation 2017.